Following a successful funding round, Deepbridge have seen a rise of 40% in subscriptions for the Life Sciences fund in comparison to last year.
Dr Savvas Neophytou, Partner and Head of Life Sciences at Deepbridge, commented:
“The past twelve months has shone a spotlight on the world-leading innovation in the UK life sciences sector like never before, and we have understandably seen significant growth in investor interest as a result.”
By following this link, you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites.